DIAGNOS to Present at Centurion One Capital 8th Annual Toronto Growth Conference
DIAGNOS Inc. (TSXV: ADK) (OTCQB: DGNOF), a pioneer in AI-driven health detection through its FLAIRE platform, will present at the Centurion One Capital 8th Annual Conference in Toronto on March 6th, 2025. The private event connects Canadian investors with promising investment opportunities.
CEO André Larente emphasized that AI will enhance medical practice by improving accuracy and efficiency. The company's focus is on revolutionizing eye health through AI technologies, particularly in the optometry market which includes over 300,000 sites globally. Their CARA (Computer Assisted Retina Analysis) system provides enhanced retinal image analysis for efficient patient screening.
DIAGNOS has recently secured a partnership with the industry's largest player, validating their technology and expanding their market presence. The company is also seeing a revival in government-related business initiatives, indicating a growth phase.
DIAGNOS Inc. (TSXV: ADK) (OTCQB: DGNOF), pioniere nella rilevazione della salute tramite intelligenza artificiale attraverso la sua piattaforma FLAIRE, presenterà alla Centurion One Capital 8ª Conferenza Annuale a Toronto il 6 marzo 2025. L'evento privato connette investitori canadesi con opportunità di investimento promettenti.
Il CEO André Larente ha sottolineato che l'IA migliorerà la pratica medica aumentando l'accuratezza e l'efficienza. L'azienda si concentra sulla rivoluzione della salute oculare attraverso tecnologie AI, in particolare nel mercato dell'optometria che comprende oltre 300.000 siti a livello globale. Il loro sistema CARA (Computer Assisted Retina Analysis) fornisce un'analisi migliorata delle immagini retiniche per uno screening efficiente dei pazienti.
DIAGNOS ha recentemente ottenuto una partnership con il più grande attore del settore, validando la propria tecnologia e ampliando la propria presenza sul mercato. L'azienda sta anche assistendo a una ripresa delle iniziative commerciali legate al governo, indicando una fase di crescita.
DIAGNOS Inc. (TSXV: ADK) (OTCQB: DGNOF), pionero en la detección de salud impulsada por IA a través de su plataforma FLAIRE, presentará en la 8ª Conferencia Anual de Centurion One Capital en Toronto el 6 de marzo de 2025. El evento privado conecta a inversores canadienses con oportunidades de inversión prometedoras.
El CEO André Larente enfatizó que la IA mejorará la práctica médica al aumentar la precisión y la eficiencia. La empresa se centra en revolucionar la salud ocular a través de tecnologías de IA, particularmente en el mercado de la optometría, que incluye más de 300,000 sitios a nivel mundial. Su sistema CARA (Computer Assisted Retina Analysis) proporciona un análisis mejorado de imágenes retinianas para un cribado eficiente de pacientes.
DIAGNOS ha asegurado recientemente una asociación con el jugador más grande de la industria, validando su tecnología y ampliando su presencia en el mercado. La empresa también está viendo un resurgimiento en las iniciativas comerciales relacionadas con el gobierno, lo que indica una fase de crecimiento.
DIAGNOS Inc. (TSXV: ADK) (OTCQB: DGNOF)은 FLAIRE 플랫폼을 통해 AI 기반 건강 감지의 선구자로, 2025년 3월 6일 토론토에서 열리는 Centurion One Capital 제8회 연례 회의에서 발표할 예정입니다. 이 사적인 행사는 캐나다 투자자들과 유망한 투자 기회를 연결합니다.
CEO 앙드레 라렌트는 AI가 정확성과 효율성을 향상시켜 의료 관행을 개선할 것이라고 강조했습니다. 회사는 전 세계 30만 개 이상의 사이트를 포함하는 안과 시장을 통해 AI 기술로 눈 건강을 혁신하는 데 주력하고 있습니다. 그들의 CARA (Computer Assisted Retina Analysis) 시스템은 효율적인 환자 선별을 위한 향상된 망막 이미지 분석을 제공합니다.
DIAGNOS는 최근 업계 최대 기업과 파트너십을 체결하여 기술을 검증하고 시장 존재감을 확장했습니다. 또한 회사는 정부 관련 비즈니스 이니셔티브의 부활을 보고하고 있으며, 이는 성장 단계에 있음을 나타냅니다.
DIAGNOS Inc. (TSXV: ADK) (OTCQB: DGNOF), pionnier de la détection de la santé basée sur l'IA grâce à sa plateforme FLAIRE, présentera à la 8e Conférence Annuelle de Centurion One Capital à Toronto le 6 mars 2025. Cet événement privé connecte les investisseurs canadiens avec des opportunités d'investissement prometteuses.
Le CEO André Larente a souligné que l'IA améliorera la pratique médicale en augmentant la précision et l'efficacité. L'entreprise se concentre sur la révolution de la santé oculaire grâce aux technologies d'IA, en particulier sur le marché de l'optométrie qui comprend plus de 300 000 sites dans le monde. Leur système CARA (Computer Assisted Retina Analysis) fournit une analyse améliorée des images rétiniennes pour un dépistage efficace des patients.
DIAGNOS a récemment sécurisé un partenariat avec le plus grand acteur du secteur, validant sa technologie et élargissant sa présence sur le marché. L'entreprise constate également un renouveau des initiatives commerciales liées au gouvernement, ce qui indique une phase de croissance.
DIAGNOS Inc. (TSXV: ADK) (OTCQB: DGNOF), ein Pionier in der KI-gestützten Gesundheitsüberwachung durch seine FLAIRE-Plattform, wird am 6. März 2025 auf der 8. Jahrestagung von Centurion One Capital in Toronto präsentieren. Die private Veranstaltung verbindet kanadische Investoren mit vielversprechenden Investitionsmöglichkeiten.
CEO André Larente betonte, dass KI die medizinische Praxis durch verbesserte Genauigkeit und Effizienz optimieren wird. Das Unternehmen konzentriert sich darauf, die Augengesundheit durch KI-Technologien zu revolutionieren, insbesondere im Bereich der Optometrie, der weltweit über 300.000 Standorte umfasst. Ihr CARA (Computer Assisted Retina Analysis)-System bietet eine verbesserte Analyse von Netzhautbildern für ein effizientes Screening von Patienten.
DIAGNOS hat kürzlich eine Partnerschaft mit dem größten Akteur der Branche gesichert, was die Technologie validiert und die Marktpräsenz erweitert. Das Unternehmen verzeichnet auch eine Wiederbelebung von staatlich geförderten Geschäftsinitiativen, was auf eine Wachstumsphase hinweist.
- None.
- None.
Brossard, Quebec--(Newsfile Corp. - February 24, 2025) - Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) ("DIAGNOS" or the "Corporation"), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce that it will be presenting at the Centurion One Capital 8th Annual Conference in Toronto, Canada March 6th 2025.
This private event brings together the largest Canadian base of investors looking for the next best investments. DIAGNOS is part of this prestigious event to present its Artificial Intelligence solution for the medical market. DIAGNOS will demonstrate that the market they are going after can be a worldwide success.
"Artificial intelligence will not replace doctors, rather it will empower physicians to practice better medicine with greater accuracy and increase efficiency at unmatched cost. With more data generated than ever, Artificial Intelligence can harness this wealth of information to significantly enhance patient outcomes," said André Larente, CEO of DIAGNOS.
"DIAGNOS is committed to revolutionizing eye health through Artificial Intelligence technologies," added André. "Our expertise in Artificial Intelligence driven diagnostics is helping to improve patient outcomes worldwide. The optometry market comprises over 300,000 sites globally. Our recent partnership with the largest player in the industry has not only validated our technology, but will significantly boost our visibility. Additionally, our government-related business initiatives are resuming, marking an exciting phase of growth for DIAGNOS."
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.
Additional information is available at www.diagnos.ca and www.sedarplus.com.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- 30 -
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242074
FAQ
When is DIAGNOS (DGNOF) presenting at the Centurion One Capital Conference in 2025?
What is DIAGNOS's CARA system used for in healthcare?
How many optometry sites can DIAGNOS (DGNOF) potentially serve globally?
What recent partnership has DIAGNOS (DGNOF) secured in the optometry industry?
What is DIAGNOS's FLAIRE platform?
